• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

慢性肝病住院患者的凝血障碍并不能预防静脉血栓栓塞症。

Coagulopathy does not protect against venous thromboembolism in hospitalized patients with chronic liver disease.

机构信息

MSPH, Division of Pulmonary, Critical Care, and Environmental Medicine, University of Missouri-Columbia, 5 Hospital Dr, CE428 CS&E Bldg, Columbia, MO 65212, USA.

出版信息

Chest. 2010 May;137(5):1145-9. doi: 10.1378/chest.09-2177. Epub 2009 Dec 29.

DOI:10.1378/chest.09-2177
PMID:20040609
Abstract

BACKGROUND

It is uncertain whether pathologically prolonged international normalized ratio (INR) seen in chronic liver disease (CLD) protects against venous thromboembolism (VTE). Previous studies reported VTE incidence of 0.5% to 1.9% in patients with CLD. We sought to evaluate VTE incidence among hospitalized patients with CLD according to INR levels.

METHODS

This was a retrospective cohort study performed at a tertiary university hospital. We included all adult patients admitted with a primary diagnosis of CLD over a 7-year period. The primary outcome was the development of VTE during hospital stay. Patients were divided into quartiles according to their highest admission INR. VTE events and prophylaxis rates were compared among INR quartiles.

RESULTS

During the allotted 7-year period, we included 190 patients. Of these, 12 developed VTE events, yielding a VTE incidence of 6.3%. There was no significant difference in the incidence of VTE between INR quartiles. Hospital mortality rates were higher in the higher INR quartiles than in the lower ones (P < .001), but hospital length of stay was not significantly different. Of the patients with documented VTE, one (4.2%) was Child-Pugh stage A, three (4.6%) were stage B, and eight (8.0%) were stage C (P = .602). VTE prophylaxis was not used in 75% of patients.

CONCLUSIONS

An elevated INR in the setting of CLD does not appear to protect against the development of hospital-acquired VTE. The notion that "auto-anticoagulation" protects against VTE is unfounded. Use of DVT prophylaxis was extremely low in this population.

摘要

背景

慢性肝脏疾病(CLD)患者的国际标准化比值(INR)延长是否能预防静脉血栓栓塞症(VTE)尚不确定。此前的研究报道,CLD 患者的 VTE 发生率为 0.5%至 1.9%。我们旨在评估根据 INR 水平住院 CLD 患者的 VTE 发生率。

方法

这是一项在三级大学医院进行的回顾性队列研究。我们纳入了在 7 年期间内因原发性 CLD 入院的所有成年患者。主要结局是住院期间发生 VTE。患者根据最高入院 INR 分为 quartiles。比较了 INR quartiles 之间的 VTE 事件和预防治疗率。

结果

在规定的 7 年期间,我们纳入了 190 例患者。其中,12 例发生了 VTE 事件,VTE 发生率为 6.3%。INR quartiles 之间的 VTE 发生率无显著差异。较高 INR quartiles 的住院死亡率高于较低 quartiles(P<.001),但住院时间无显著差异。有记录的 VTE 患者中,1 例(4.2%)为 Child-Pugh 分级 A,3 例(4.6%)为分级 B,8 例(8.0%)为分级 C(P=.602)。75%的患者未使用 VTE 预防治疗。

结论

CLD 患者 INR 升高似乎并不能预防医院获得性 VTE 的发生。“自身抗凝”可预防 VTE 的观点是没有依据的。该人群中 DVT 预防治疗的使用率极低。

相似文献

1
Coagulopathy does not protect against venous thromboembolism in hospitalized patients with chronic liver disease.慢性肝病住院患者的凝血障碍并不能预防静脉血栓栓塞症。
Chest. 2010 May;137(5):1145-9. doi: 10.1378/chest.09-2177. Epub 2009 Dec 29.
2
A Retrospective Cohort Analysis of Pharmacologic VTE Prophylaxis and Padua Prediction Score in Hospitalized Patients With Chronic Liver Disease.慢性肝病住院患者药物性静脉血栓栓塞预防与帕多瓦预测评分的回顾性队列分析
J Pharm Pract. 2017 Feb;30(1):58-63. doi: 10.1177/0897190015611570. Epub 2016 Jul 9.
3
Evaluation of pharmacologic prophylaxis for venous thromboembolism in patients with chronic liver disease.评估慢性肝病患者的静脉血栓栓塞症药物预防。
Pharmacotherapy. 2013 Apr;33(4):375-82. doi: 10.1002/phar.1218.
4
Risk of hemorrhage in patients with chronic liver disease and coagulopathy receiving pharmacologic venous thromboembolism prophylaxis.接受药物性静脉血栓栓塞预防的慢性肝病和凝血障碍患者的出血风险。
Pharmacotherapy. 2014 Oct;34(10):1043-9. doi: 10.1002/phar.1464. Epub 2014 Jul 23.
5
Evaluation of venous thromboembolism prophylaxis in patients with chronic liver disease.评估慢性肝脏疾病患者的静脉血栓栓塞症预防措施。
J Hosp Med. 2013 Oct;8(10):569-73. doi: 10.1002/jhm.2086. Epub 2013 Sep 20.
6
Risk of venous thromboembolism in patients with chronic liver disease and the utility of venous thromboembolism prophylaxis.慢性肝病患者发生静脉血栓栓塞的风险及静脉血栓栓塞预防的效用
Ann Pharmacother. 2012 Jun;46(6):873-8. doi: 10.1345/aph.1Q726. Epub 2012 May 8.
7
Suboptimal use of pharmacological venous thromboembolism prophylaxis in cirrhotic patients.肝硬化患者药物性静脉血栓栓塞预防措施的使用未达最佳标准。
Intern Med J. 2018 Sep;48(9):1056-1063. doi: 10.1111/imj.13766.
8
Incidence of hospital-acquired venous thromboembolic codes in medical patients hospitalized in academic medical centers.学术医疗中心住院内科患者医院获得性静脉血栓栓塞编码的发生率。
J Hosp Med. 2014 Apr;9(4):221-5. doi: 10.1002/jhm.2159. Epub 2014 Feb 5.
9
Venous thromboembolism in coagulopathic surgical intensive care unit patients: is there a benefit from chemical prophylaxis?凝血功能障碍的外科重症监护病房患者的静脉血栓栓塞:化学预防有好处吗?
J Trauma. 2011 Jun;70(6):1398-400. doi: 10.1097/TA.0b013e318217868d.
10
Majority of Total Joint Arthroplasties Are Subtherapeutic on Warfarin at Time of Discharge: Another Reason to Avoid Warfarin as a Venous Thromboembolism Prophylaxis?大多数全关节置换术患者在出院时华法林的治疗剂量不足:是否应避免将华法林作为静脉血栓栓塞症预防药物?
J Arthroplasty. 2018 Sep;33(9):2787-2791. doi: 10.1016/j.arth.2018.04.040. Epub 2018 May 3.

引用本文的文献

1
Thromboelastography for the evaluation of coagulation function in patients with hepatic echinococcosis during the perioperative period: a retrospective study.血栓弹力图评估肝包虫病患者围手术期凝血功能的回顾性研究
Front Oncol. 2025 Aug 21;15:1603148. doi: 10.3389/fonc.2025.1603148. eCollection 2025.
2
Development and validation of a nomogram for predicting postoperative venous thromboembolism risk in patients with hepatocellular carcinoma.预测肝细胞癌患者术后静脉血栓栓塞风险的列线图的开发与验证
World J Gastrointest Oncol. 2025 Jun 15;17(6):105790. doi: 10.4251/wjgo.v17.i6.105790.
3
Phytonadione Utilization and the Risk of Bleeding in Chronic Liver Disease.
维生素K1的使用与慢性肝病患者的出血风险
Hosp Pharm. 2024 Dec;59(6):660-665. doi: 10.1177/00185787241269114. Epub 2024 Aug 12.
4
Viscoelastic Hemostatic Testing as a Diagnostic Tool for Hypercoagulability in Liver Transplantation: A Narrative Review.黏弹性止血检测作为肝移植高凝状态诊断工具的叙述性综述
J Clin Med. 2024 Oct 21;13(20):6279. doi: 10.3390/jcm13206279.
5
A Comprehensive Review of Risk Factors and Thrombophilia Evaluation in Venous Thromboembolism.静脉血栓栓塞症的危险因素及易栓症评估综合综述
J Clin Med. 2024 Jan 9;13(2):362. doi: 10.3390/jcm13020362.
6
The Challenge of Anticoagulation in Liver Cirrhosis.肝硬化患者抗凝治疗面临的挑战
Visc Med. 2024 Jan;39(6):169-176. doi: 10.1159/000535438. Epub 2023 Dec 21.
7
Prevalence of chronic venous insufficiency and deep vein thrombosis in cirrhotic patients.肝硬化患者慢性静脉功能不全和深静脉血栓形成的患病率。
Front Med (Lausanne). 2023 Sep 27;10:1214517. doi: 10.3389/fmed.2023.1214517. eCollection 2023.
8
Management of Patients Treated with Direct Oral Anticoagulants in Clinical Practice and Challenging Scenarios.临床实践及复杂情况下接受直接口服抗凝剂治疗患者的管理
J Clin Med. 2023 Sep 13;12(18):5955. doi: 10.3390/jcm12185955.
9
The Yin and the Yang of Hemostasis in End-Stage Liver Disease.终末期肝病止血的阴阳平衡
J Clin Med. 2023 Sep 4;12(17):5759. doi: 10.3390/jcm12175759.
10
Impact of Vitamin K Administration on Elevated International Normalized Ratio in Chronic Liver Disease.维生素 K 给药对慢性肝病中国际标准化比值升高的影响。
Clin Appl Thromb Hemost. 2023 Jan-Dec;29:10760296231164642. doi: 10.1177/10760296231164642.